Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

NCT04287686 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Without CDE Approval

Conditions

COVID-19

Interventions

DRUG: Recombinant human angiotensin-converting enzyme 2 (rhACE2)

Sponsor

The First Affiliated Hospital of Guangzhou Medical University